UPDATE 1-Fosun Pharma to import 100 mln doses of BioNTech's

UPDATE 1-Fosun Pharma to import 100 mln doses of BioNTech's COVID-19 vaccine to China


UPDATE 2-Fosun Pharma to buy 100 mln doses of BioNTech's COVID-19 vaccine for mainland China
Reuters
12/16/2020
(Adds profit breakdown, other supply deals)
Dec 16 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd on Wednesday said it will buy at least 100 million doses of a COVID-19 vaccine from Germany's BioNTech SE for use in mainland China next year, if the vaccine receives approval.
The Chinese government has not announced supply deals with Western drugmakers, which instead have partnered local firms.
Fosun said it will be entitled to 60% of annual gross profit from sales of doses that it will make from imported bulk ingredients, and 65% of profit from sales of doses imported ready for use.

Related Keywords

China , Beijing , Bengaluru , Karnataka , India , United Kingdom , Singapore , Nikhil Kurian Nainan , Roxanne Liu , Shri Navaratnam , Fosun Pharma , Pfizer , Shanghai Fosun Pharmaceutical Group , Reuters , Fosun Pharmaceutical Group , Jiangsu Province , Beijing Editing , சீனா , பெய்ஜிங் , பெங்களூரு , கர்நாடகா , இந்தியா , ஒன்றுபட்டது கிஂக்டம் , சிங்கப்பூர் , நிகில் குரியன் நைனன் , ரோக்ஷ்ண்னே லியூ , திரு நவரட்னம் , ஃபைசர் , ராய்ட்டர்ஸ் , பெய்ஜிங் திருத்துதல் ,

© 2025 Vimarsana